1.Association of Hearing Loss with Noise Exposure Time in Farm Machinery Operators.
Hiroyuki TAKEZAWA ; Masanori KONISHI ; Ryoukichi IMAI ; Masako WATANABE
Journal of the Japanese Association of Rural Medicine 1998;47(4):583-588
The aim of this study is to clarify the relations between the hearing impairment of farmers and exposure to noise generated by agricultural machines. Some studies have revealed that the equivalent continuous sound level (Leq) from agricultural machines exceeds 80dB (A). But the noise -induced hearing loss experienced by farm machine operators has not received much attention, probably because they are self-employed and their working hours are irregular.
We surveyed 1, 368 farmers, aged 17 to 76 (male 828, female 480), about working hours. We also tested their hearing levels at 1kHz and 4kHz. It was found that 22.3% of the farmers (305 of 1, 368) had some hearing impairment. In the hearing-impaired group, the mean length of working hours on tracters or other machines was 24, 689 ± 21, 155.13 hours. In the healthy group, the mean length of working hours was 16, 077. 65 ± 17, 623. 69 hours. A statistically significant difference was evident in the above results. As the operating hours increased, the incidence of the hearing impairment also increased. To avoid the biases of aging, we examined the results according to each age group. In the 40, 50, and 60-year-old age groups, the operating hours of the hearing impaired group were longer than those of the healthy group. We concluded that the amount of noise exposure probably affects farmers' hearing.
2.Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms.
Masanori NOGUCHI ; Tatsuyuki KAKUMA ; Katsuro TOMIYASU ; Akira YAMADA ; Kyogo ITOH ; Fumiko KONISHI ; Shoichiro KUMAMOTO ; Kuniyoshi SHIMIZU ; Ryuichiro KONDO ; Kei MATSUOKA
Asian Journal of Andrology 2008;10(5):777-785
AIMTo evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5alpha-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS).
METHODSIn this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects.
RESULTSG. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95% confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects.
CONCLUSIONThe extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.
Aged ; Drugs, Chinese Herbal ; administration & dosage ; adverse effects ; Ethanol ; Humans ; Male ; Middle Aged ; Phytotherapy ; Placebos ; Reishi ; Solvents ; Treatment Outcome ; Urination Disorders ; drug therapy ; Urodynamics ; drug effects
3.Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study.
Masanori NOGUCHI ; Tatsuyuki KAKUMA ; Katsuro TOMIYASU ; Yoshiko KURITA ; Hiroko KUKIHARA ; Fumiko KONISHI ; Shoichiro KUMAMOTO ; Kuniyoshi SHIMIZU ; Ryuichiro KONDO ; Kei MATSUOKA
Asian Journal of Andrology 2008;10(4):651-658
AIMTo conduct a double-blind, placebo-controlled randomized and dose-ranging study to evaluate the safety and efficacy of the extract of Ganoderma lucidum (G. lucidum) in men with lower urinary tract symptoms (LUTS).
METHODSWe enrolled male volunteers (> or = 50 years) with an International Prostate Symptom Score (IPSS; questions 1-7) > or = 5 and a prostate-specific antigen (PSA) value < 4 ng/mL. Volunteers were randomized into groups of placebo (n = 12), G. lucidum of 0.6 mg (n = 12), 6 mg (n = 12) or 60 mg (n = 14), administered once daily. Efficacy was measured as a change from baseline in IPSS and the peak urine flow rate (Q(max)). Prostate volume and residual urine were estimated by ultrasonography, and blood tests, including PSA levels, were measured at baseline and at the end of the treatment.
RESULTSThe overall administration was well tolerated, with no major adverse effects. Statistical significances in the magnitude of changes between the experimental groups were observed at weeks 4 and 8. No changes were observed with respect to Q(max), residual urine, prostate volume or PSA levels.
CONCLUSIONThe extract of G. lucidum was well tolerated and an improvement in IPSS was observed. The recommended dose of the extract of G. lucidum is 6 mg in men with LUTS.
Aged ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Humans ; Male ; Middle Aged ; Phytotherapy ; methods ; Pilot Projects ; Prostate ; pathology ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; drug therapy ; Reishi ; Treatment Outcome ; Urinary Bladder, Overactive ; drug therapy ; Urinary Incontinence ; drug therapy